Enniskillen retreat provides support for those battling Pulmonary Fibrosis
Speaking at the opening, Clare Donohoe, Trustee of Pulmonary Fibrosis NI (PFNI), described the moment as both an honour and a deeply personal one. The retreat, she explained, is more than just a building; it is a sanctuary offering relief to those facing the challenges of the disease.
'For me, today is also bittersweet,' she shared, reflecting on her late husband Tom's battle with Idiopathic Pulmonary Fibrosis (IPF). Tom, a devoted husband and father, was diagnosed in 2019 at the age of 43 after initially presenting with a persistent cough. 'Devastation hit home when I researched the disease,' Mrs. Donohoe said, recounting the impact on their young family. Despite the challenges, Tom remained stoic and hopeful, continuing to work while quietly managing his diagnosis.
In June 2024, Mrs. Donohoe took voluntary redundancy from her role as a lecturer to care for Tom as he navigated the later stages of the disease while awaiting a transplant at The Freeman Hospital in Newcastle. However, the transplant never came. In August 2024, Tom's condition worsened, and after three weeks in intensive care at the South West Acute Hospital, he passed away on September 1.
Despite her grief, his wife emphasised Tom's instrumental role in securing the property for Inis Ceithleann Retreat. A chance conversation with a workman during a drive led to an introduction to the owner, David Wilson, and eventually, the acquisition of the property by PFNI in June 2024.
'Whilst Tom's loss is deeply felt, his legacy lives on in the sanctuary of Inis Ceithleann Retreat, and in the hope and respite it will offer to so many who sadly are on the pulmonary fibrosis journey,' she said.
Mrs. Donohoe extended heartfelt thanks to the many supporters, trustees, funders, and friends who made the retreat possible. She also acknowledged Paul Shannon, William Foster, and Sean McCarroll from Balcas for their tribute to Tom—a bespoke bench crafted in his memory.
Mr. Foster said: 'This bench is more than just a seat; it's a place for reflection, comfort, and connection. As visitors rest here, may they find solace and draw inspiration from Tommy's life and the love he shared with all who knew him.
'Tommy's absence leaves a void, but his spirit lives on in the laughter we shared and the memories we cherish. Let this bench serve as a lasting tribute to a remarkable man whose impact will be felt for generations to come.'
The opening of Inis Ceithleann Retreat represents a beacon of hope for those affected by Pulmonary Fibrosis, ensuring that families have a place of peace, sanctuary, and renewal in their time of need.
Tom McMillan, Chair of Pulmonary Fibrosis NI (PFNI), opened the event with a welcome and introduction. Dr. Nadia Chadkuri, a PFNI Trustee, also spoke, followed by patient and trustee Una McMillan. Paddy McNamara, a patient and transplant recipient, shared his experiences and insights as an ambassador for PFNI. Representatives from the community and political parties also attended the opening.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
3 days ago
- Associated Press
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2025, and provided a general business update. 'This quarter, we remained on track with the strategic objectives we outlined at the start of the year, including the completion of enrollment in our pivotal Phase 3 PHOENIX trial — an important milestone in our development efforts for people living with geographic atrophy,' said Dr. Tom Lin, Chairman and CEO of Belite Bio. 'We also received Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease from the FDA, underscoring its potential as the first-ever treatment for this patient population and acknowledging the significant unmet need for people living with this debilitating disease. With the DRAGON trial on track to complete by the end of this year, we remain focused on advancing Tinlarebant toward key clinical and regulatory milestones.' Second Quarter 2025 Business Highlights and Upcoming Milestones: Clinical Highlights Tinlarebant (LBS-008) is an oral, potent, once-daily, retinol binding protein 4 (RBP4) antagonist that decreases RBP4 levels in the blood and reduces vitamin A (retinol) delivery to the eye without disrupting systemic retinol delivery to other tissues. Vitamin A is critical for normal vision but can accumulate as toxic byproducts in individuals affected with STGD1 and GA, the advanced form of dry age-related macular degeneration (AMD), leading to retinal cell death and loss of vision. Corporate Highlights Second Quarter 2025 Financial Results: Current Assets: As of June 30, 2025, the Company had $149.2 million in cash, liquidity funds, time deposits, and U.S treasury bills. R&D Expenses: For the three months ended June 30, 2025, research and development expenses were $11.0 million compared to $9.1 million for the same period in 2024. For the six months ended June 30, 2025, research and development expenses were $20.4 million compared to $15.8 million for the same period in 2024. The increase in research and development expenses in both the quarter and year-to-date was primarily attributable to (i) higher pass-through expenses related to the PHOENIX trial and manufacturing expenses payments, partially offset by lower DRAGON trial expenses and a development milestone payment for the completion of a phase 2 trial in 2024; (ii) an increase in share-based compensation expenses. G&A Expenses: For the three months ended June 30, 2025, general and administrative expenses were $6.5 million compared to $1.4 million for the same period in 2024. For the six months ended June 30, 2025, general and administration expenses were $12.7 million compared to $3.0 million for the same period in 2024. The increase in general and administrative expenses in both the quarter and year-to-date was primarily due to an increase in share-based compensation expenses. Other Income: For the three months ended June 30, 2025, other income was $1.3 million compared to $1.0 million for the same period in 2024. For the six months ended June 30, 2025, other income was $2.5 million compared to $1.4 million for the same period in 2024. The increase in both the quarter and year-to-date was attributed to interest from time deposits and U.S. treasury bills. Net Loss: For the three months ended June 30, 2025, the Company reported a net loss of $16.3 million, compared to a net loss of $9.5 million for the same period in 2024. For the six months ended June 30, 2025, the Company reported a net loss of $30.6 million, compared to a net loss of $17.4 million for the same period in 2024. Webcast Information Belite Bio will host a webcast on Monday, August 11, 2025, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update. To join the webcast, please visit A replay will be available for approximately 90 days following the event. About Belite Bio Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite's lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at Important Cautions Regarding Forward Looking Statements This press release contains forward-looking statements about future expectations and plans, as well as other statements regarding matters that are not historical facts. These statements include but are not limited to statements regarding the potential implications of clinical data for patients, and Belite Bio's advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates, and any other statements containing the words 'expect', 'hope' and similar expressions. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Belite Bio's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the timing to complete relevant clinical trials and/or to receive the interim/final data of such clinical trials; the timing to submit trial data to regulatory authorities for drug approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Belite Bio's drug candidates; the potential efficacy of Tinlarebant, as well as those risks more fully discussed in the 'Risk Factors' section in Belite Bio's filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Media and Investor Relations Contact: Jennifer Wu [email protected] Julie Fallon [email protected]
Yahoo
6 days ago
- Yahoo
I did the 90/90 hip stretch for a week — and my mobility improved in a way I didn't expect
When you buy through links on our articles, Future and its syndication partners may earn a commission. My challenges for Tom's Guide usually involve lifting weights, or using my body weight, to build strength and remind me I'm not in the enviable shape I think I am. The challenges are never less than interesting, they are often surprising, and some have impressed me to the point I have continued to use them in my exercise regime (you know when a move is right for you). So when my editor suggested the 90/90 stetch, I thought, 'This is different.' Then I thought, 'I wonder what it is.' This is not because I'm an ignoramus, but because, like most people, I don't stretch as much as I should. As someone interested in fitness and remaining physically strong, this is the strategy of, well, an ignoramus. So I was more than keen to give it a go. Was it a life-changing experience? I'm not a man given to hyperbole, so, no, of course not. Was it a revealing, fascinating, frustrating and, ultimately, greatly beneficial? It sure was. What is the 90/90 stretch? This is an immensely effective hip-mobility exercise. Most of us take our hips for granted, and it's only when we're dancing at a wedding that we realise they're not as loose as they once were, or ought to be. Hip mobility and flexibility are vital for general day-to-day activities, as well as for exercise and sports. However, because the muscles, tendons, and joints in the area simply do their job, we often assume they don't require attention. Out of sight, out of mind, until one day you drop your keys and are reduced to hoping someone short is nearby to pick them up for you. Good hip flexibility can also help relieve lower back pain, which, at any given time, afflicts about a quarter of US adults. The 90/90 works the hips internally and externally at the same time, which is rare for one move. It targets a variety of muscles, including the adductors, abductors, and glutes, as well as some of the hard-to-hit but important muscles such as the psoas and the piriformis. Crucially, it also works the hip capsule, specialised ligaments that stabilise the hip joint. This move asks a lot but boy, it delivers. How do I do the 90/90 stretch? Begin by sitting on the floor (I suggest you use a yoga mat for this move), with your right leg bent in front of you at a 90-degree angle, hip rotated out. This means the outside of your leg will be resting on the floor. Your foot should be in a neutral position, so don't point it. It, too, should form a 90-degree angle with your lower leg. Your thigh should be directly in front of your chest. If you feel you are leaning to the right, slide your leg slightly closer to your body, maintaining the angle as best you can. Position your left leg to your left side, again at a 90-degree angle, hip rotated internally. This means the inside of your leg will be resting on the floor. Make sure your back knee is in line with your hip. If you feel tightness in the hip, bring your leg forward a little, but again, maintain the angle. Keeping your legs in this position, and with your back straight, chest up, lean from the hips to feel a stretch through your right hip and glutes. Use your right arm to steady yourself as you increase the stretch. Breathe slowly and evenly, and hold the stretch for 60 seconds. Repeat on the other side and aim for two reps on each side. I did the 90/90 hip stretch every day for a week — here's what happened I admit I went into this challenge with the cockiness of the clueless. I figured that I'd have no trouble because I wasn't lifting, lowering, lunging, pushing, or otherwise using my muscles. And I already do some stretching. Not nearly enough, as it happens. Listen to your body On the first day, I got into position, though not as smoothly as I'd expected, as there is something counterintuitive about the shape the body makes with the two legs. It did not feel natural, and as I tried to relax and let my legs rest easily on the floor, I sensed a stretch not in my hips, but in my lower back and across my core. 'This can't be right,' I thought. It wasn't painful, but it was not the stretch I was expecting. I reset myself and tried again, but the result was the same. Afterwards, I decided my torso was twisting to maintain what I thought was the right position. Watch what you're doing On day two, I placed a two-foot mirror in front of me, and my indignity was complete. But I could immediately see that I was indeed leaning left or right, depending on which leg was in front. I corrected my position and held it for 40 seconds on each side, but while I felt a deep stretch, it was still not where it needed to be. And just like that… On day three, everything fell into place. I got into position, but shifted each leg slightly while holding the 90-degree angle, and I suddenly felt the stretch exactly where I was supposed to feel it, and not across the back or through the core. With this move, feel free to tweak things but maintain good form; you'll be amazed at the difference even a couple of inches makes. From the correct position, I was able to lean into the stretch and hold it for a minute on each side. I did this twice. Over the following few days, I increased the time to two minutes on each side, twice, paying attention to my breathing and always focusing on the location of the stretch. This move did not instantly improve hip mobility and flexibility, of course, but I did enjoy that deeply satisfying feeling of a stretch, and when I rose from my position, feeling fleetingly at one with my surroundings, I almost said 'Namaste.' Almost. Try this stretch I can't put it any plainer than that. I found it enormously beneficial for the entire hip area, but even getting into the correct position felt like a small triumph. I will continue to get myself into the right position, and even though I won't be able to see the benefits, I will know it's working. That said, I still refuse to dance. It's my gift to the world. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button. More from Tom's Guide Forget tight hips — try these 5 mobility moves to unlock stiff hips and build stronger glutes I'm a personal trainer — here's 3 hip-opening exercises to reduce stiffness and boost lower-body mobility This routine is designed to improve your lower body's range of motion, increase blood flow and enhance joint mobility
Yahoo
7 days ago
- Yahoo
Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF Closed $115 million underwritten offering with expected cash runway into 2029 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., Aug. 7, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced financial results for the quarter ended June 30, 2025, and provided business updates. "The recently received full data set from our CORAL trial for chronic cough in patients with IPF bolsters the statistically-significant topline results presented in June. This data marks a major milestone for Trevi as it shows consistency and clinically meaningful benefit for these patients," said Jennifer Good, President and CEO of Trevi Therapeutics. "Chronic cough is a debilitating and underserved condition for patients with IPF, and these results, along with the positive RCC data from our RIVER trial announced earlier this year, reinforce our belief in Haduvio's potential to transform care of chronic cough and the lives of these patients. We expect our current cash and investments to provide us with cash runway into 2029, giving us the financial strength to advance Haduvio through late-stage development and several key clinical milestones, as well as enabling pre-commercial planning activities." Second Quarter 2025 Financial Results and Recent Business Highlights Positive topline results from the Phase 2b CORAL trial evaluating Haduvio for the treatment of chronic cough in patients with IPF (N=165) were announced in June 2025. Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups. The 108 mg BID, 54 mg BID, and 27 mg BID dose groups achieved statistically-significant reductions from Baseline of 60.2% (p<0.0001), 53.4% (p<0.0001), and 47.9% (p<0.01), respectively, compared to a placebo reduction from Baseline of 16.9%.1 The Company plans to request an End-of-Phase 2 meeting with the FDA in the fourth quarter of 2025 to align on the Phase 3 program. The Company is preparing to initiate the Phase 3 program in the first half of 2026. Additional analyses from the Phase 2b CORAL trial showed positive results with Haduvio on the Leicester Cough Questionnaire (LCQ) Total Score for the 108 mg BID and 54 mg BID dose groups, increasing the LCQ score by 3.4 points (p=0.01) and 3.7 points (p=0.01), respectively. A 1.3-point increase from Baseline is considered clinically meaningful. The LCQ is considered an important measure of quality of life for patients suffering from chronic cough. Completed a $115 million underwritten offering in June 2025, enabling continued advancement of Haduvio's clinical programs. The Company ended the second quarter of 2025 with $203.9 million in cash, cash equivalents and marketable securities, with expected cash runway into 2029. Second Quarter 2025 Financial HighlightsResearch and development (R&D) expenses: R&D expenses for the second quarter of 2025 decreased to $9.4 million from $10.0 million in the same period in 2024, primarily due to decreased clinical development expenses for the Company's Phase 2a RIVER trial, Human Abuse Potential (HAP) study, and Phase 2b CORAL trial, all of which were actively enrolling patients in the prior year period. These decreases were partially offset by increased costs for the Company's recently initiated Phase 1 drug-drug interaction study, and personnel and related expenses. General and administrative (G&A) expenses: G&A expenses for the second quarter of 2025 increased to $4.3 million from $3.3 million in the same period in 2024, primarily due to an increase in professional fees, and personnel and related expenses. Other Income, net: Other Income, net for the second quarter of 2025 increased to $1.4 million from $0.9 million in the same period in 2024, primarily due to an increase in interest income from higher invested cash equivalent and marketable securities balances. Net loss: For the second quarter of 2025, the Company reported a net loss of $12.3 million compared to the net loss of $12.4 million in the same period in 2024. Conference Call/Webcast To participate in the live conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call. No code is necessary for access. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at An archived replay of the webcast will also be available for 30 days on the Company's website following the event. Upcoming Meetings The Company plans to participate in the following events: August 11-13: Stifel's 2025 Biotech Summer Summit September 3-5: Wells Fargo 2025 Healthcare Conference September 3-5: Cantor Global Healthcare Conference 2025 September 8-10: H.C. Wainwright & Co. 27th Annual Global Investment Conference September 8-10: Morgan Stanley 23rd Annual Global Healthcare Conference September 17-19: 2025 Leerink Partners Biopharma Summit September 27-October 1: European Respiratory Society (ERS) Congress About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in chronic cough patients with IPF and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Chronic cough is a highly prevalent condition, impacting up to 85% of patients with IPF. There are ~150,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients. Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip) and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit and follow Trevi on X (formerly Twitter) and LinkedIn. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Trevi's business plans and objectives, including future plans or expectations for Haduvio and plans and timing with respect to clinical trials and clinical data, expectations regarding Trevi's uses and sufficiency of capital, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties regarding the success, cost and timing of Trevi's product candidate development activities and clinical trials; the risk that positive data from a clinical trial may not necessarily be predictive of the results of later clinical trials in the same or a different indication; uncertainties regarding Trevi's ability to execute on its strategy; uncertainties with respect to regulatory authorities' views as to the data from Trevi's clinical trials and next steps in the development path for Haduvio in the United States and foreign countries; uncertainties inherent in estimating Trevi's cash runway, future expenses and other financial results, including Trevi's ability to fund future operations, including clinical trials, as well as other risks and uncertainties set forth in the quarterly report on Form 10-Q for the quarter ended March 31, 2025 filed with the Securities and Exchange Commission and in subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Trevi Therapeutics, Inc. Selected Balance Sheet Data (unaudited) (amounts in thousands)June 30,2025 December 31,2024Cash and cash equivalents$ 117,058 $ 34,097Marketable securities 86,82773,525Working capital 197,98798,919Total assets 208,339110,900Stockholders' equity 198,49399,644 Trevi Therapeutics, Inc. Selected Statement of Operations Data (unaudited) (amounts in thousands, except per share amounts)Three Months EndedJune 30, Six Months EndedJune 30,2025 2024 2025 2024Operating expenses: Research and development$ 9,389 $ 10,021 $ 17,200 $ 18,825General and administrative 4,3333,2687,9926,370Total operating expenses 13,72213,28925,19225,195Loss from operations (13,722)(13,289)(25,192)(25,195)Other income, net 1,4009292,5191,925Loss before income taxes (12,322)(12,360)(22,673)(23,270)Income tax benefit 2183216Net loss$ (12,301) $ (12,352) $ (22,641) $ (23,254)Basic and diluted net loss per common share outstanding$ (0.09) $ (0.12) $ (0.18) $ (0.23)Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted 130,350,391101,041,573124,015,763100,279,393 Investor Contact Jonathan Carlson Trevi Therapeutics, Inc. (203) 654 3286 carlsonj@ Media Contact Rosalia Scampoli 914-815-1465 rscampoli@ 1 One placebo patient with an extreme outlier value at Week 6 was excluded from the modified intent-to-treat (mITT) population. Inclusion of the patient in the placebo group would have resulted in an increased cough frequency from Baseline in the placebo group and much greater placebo-adjusted differences. View original content to download multimedia: SOURCE Trevi Therapeutics, Inc.
